
European Journal of Medicinal Chemistry p. 606 - 620 (2017)
Update date:2022-08-15
Topics:
Romero, Angel H.
Medina, Rafael
Alcala, Anamaría
García-Marchan, Yael
Nú?ez-Duran, Jorge
Lea?ez, Jacques
Mijoba, Ali
Ciangherotti, Carlos
Serrano-Martín, Xenón
López, Simón E.
With the aim to identify a potential drug candidate to treat cutaneous leishmaniasis, a series of 1-phthalazinyl hydrazones were synthesized and tested against Leishmania braziliensis parasite, one of the main responsible of this disease in the world. A structure-activity relationship permitted to identify two phthalazines containing nitroheterocyclic moiety 3l and 3m as promising new lead compounds. These compounds showed a significant antileishmanial activity against promastigote form of L. braziliensis, with EC50values in sub-micromolar and nanomolar ranges. The phthalazine 3l also displayed a selective and excellent activity against the clinically relevant intracellular amastigotes form, with a EC50value in sub-micromolar range (0.59 μM), without affecting the viability of the host cells. Oxidative stress was identified as the possible mode of action of the most active phthalazine. Considering their significant antileishmanial activity and ease synthesis, the phthalazine containing nitroheterocyclic represents a promising agent against Leishmania braziliensis for the rational design of new leads.
Shanghai Synmedia Chemical Co., Ltd
Contact:+86-21-38681880
Address:6th Floor, 11A Building, No.528 Ruiqing Road, Heqing town, Pudong new district, Shanghai China
Hangzhou Hysen Pharma co.,Ltd.
website:http://www.hysenpharma.cn/
Contact:0086-571-88298791
Address:#701,Gudun Road Hangzhou
VanderArk International Limited
Contact:86-10-82437576
Address:Qing He
Contact:+86-18653358619
Address:zibo
Suzhou Time-chem Technologies Co., Ltd.
Contact:0512-63983931/68086856
Address:No. 1326 of Binhe Road, New District, Suzhou, Jiangsu, P. R. China
Doi:10.1021/jo00417a024
(1978)Doi:10.1055/s-0034-1378376
(2014)Doi:10.1016/S0040-4039(00)70710-6
(1989)Doi:10.1002/hc.10201
(2003)Doi:10.1002/hlca.200390320
(2003)Doi:10.1007/BF00946912
()